BioSpace News Archive

Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases, announced the appointment of Richard Morris as chief financial officer.

Chimerix, Inc. announced that it will host a live conference call and audio webcast on Tuesday, November 5, 2019 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2019, and to provide an operational update..

Tabula Rasa HealthCare, Inc., a healthcare technology company advancing the field of medication safety, began services with Silver Star PACE on October, 2019 through its CareVention HealthCare™ Division.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its third quarter 2019 financial results prior to market open on Tuesday, November 5, 2019.

Gordian Surgical Ltd. a portfolio company of The Trendlines Group Ltd., is pleased to announce that it has raised $3 million. Investors included a group of Chinese investors, American physicians, and current shareholders..

From education and assessment to clinical follow through, novel technology platform transforms the delivery of genetic services to support individuals, health institutions and employers

Generation Bio, a company working to expand the reach of gene therapy through a novel construct and targeted delivery, announced that Steven Dowdy, Ph.D., a distinguished expert in cellular and molecular medicine, has joined its Scientific Advisory Board.

Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced it will report 2019 second fiscal quarter financial results after the close of U.S. financial markets on Tuesday, November 5, 2019.

Neuropore is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the underlying causes of neurodegenerative disease

FDgard®, a patented, solid-state microsphere formulation of caraway oil and l-Menthol, represents an important medical advance; there are no approved Rx drugs for Functional Dyspepsia (FD), a highly prevalent condition